OPKO Health
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other inte...
Latest News
12 days ago · marketbeat.com
What OPKO Health (OPK) Said on Its Q3 Earnings CallOPKO Health NASDAQ: OPK reported 16% growth in third-quarter revenue from continuing operations and outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference assets to Labcorp.
12 days ago · seekingalpha.com
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call TranscriptOPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue EstimatesOPKO Health (OPK) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.03 per share a year ago.
12 days ago · globenewswire.com
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial ResultsMIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026. Third Quarter 2026 and Recent Business Highlights OPKO enters into agreement with Labcorp for the sale of substantially all remaining BioReference diagnostic operations.
20 days ago · globenewswire.com
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 on Wednesday, November 4, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.
21 days ago · globenewswire.com
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for AcromegalyKIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor antagonist being developed for the treatment of acromegaly.
1 month ago · benzinga.com
OPKO Health Sheds Diagnostics Businesses in Major Labcorp DealLabcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.
2 months ago · zacks.com
Here's Why You Should Retain OPK Stock in Your Portfolio for NowOPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
2 months ago · zacks.com
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
2 months ago · marketbeat.com
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 MonthsOPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove OPK